Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
16.33
+0.45 (2.83%)
Oct 30, 2025, 9:52 AM EDT - Market open
Bicara Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Bicara Therapeutics stock have a consensus rating of "Buy" and an average price target of $25.6, which forecasts a 56.77% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $40.
Price Target: $25.6 (+56.77%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 22, 2025.
Analyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +144.95% | Aug 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $36 | Buy | Initiates | $36 | +120.45% | Aug 19, 2025 |
| Wells Fargo | Wells Fargo | Sell → Hold Upgrades $8 | Sell → Hold | Upgrades | $8 | -51.01% | May 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $41 | Strong Buy | Maintains | $44 → $41 | +151.07% | May 16, 2025 |
| Wells Fargo | Wells Fargo | Sell Initiates $8 | Sell | Initiates | $8 | -51.01% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.34
from -4.05
EPS Next Year
-2.71
from -2.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.16 | -2.06 | |
| Avg | -2.34 | -2.71 | |
| Low | -2.43 | -3.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.